Phase I trial of alpha-particle therapy with actinium-225 ((225)Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML Meeting Abstract

  


Authors: Jurcic, J. G.; Ravandi, F.; Pagel, J. M.; Park, J. H.; Smith, B. D.; Douer, D.; Levy, M. Y.; Estey, E.; Kantarjian, H. M.; Earle, D.; Cicic, D.; Scheinberg, D. A.
Abstract Title: Phase I trial of alpha-particle therapy with actinium-225 ((225)Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML
Meeting Title: 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 15 Suppl.
Meeting Dates: 2015 May 29-Jun 2
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-05-20
Language: English
ACCESSION: WOS:000358036901586
PROVIDER: wos
DOI: 10.1200/jco.2015.33.15_suppl.7050
Notes: Meeting Abstract: 7050 -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jae Hong Park
    356 Park
  2. David Scheinberg
    499 Scheinberg
  3. Dan Douer
    87 Douer
Related MSK Work